Advanced Materials and Processes Research Institute

Panbela Provides Business Update and Reports Q2 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Pancreatic cancer, Abstract, JDRF, AACR, Therapy, DSMB, MSN, Diabetes, Eflornithine, Clinical trial, Advanced Materials and Processes Research Institute, American Association for Cancer Research, PBLA, FAP, Research, NSCLC, Doctor of Philosophy, IDS, MD Anderson Cancer Center, Data monitoring committee, CPP, Acquisition, Patent, Patient, Colorectal cancer, University, DFMO, Endocrine Society, Immunology, H. Lee Moffitt Cancer Center & Research Institute, Ovarian cancer, Safety, Johns Hopkins School of Medicine, Pharmaceutical industry, Life insurance, STK11

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023.

Key Points: 
  • MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023.
  • Poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting in June 2023.
  • Research and development expenses were $4.2 million in the second quarter of 2023, compared to $20.0 million in the second quarter of 2022.
  • Notes payable, plus accrued interest, on the balance sheet, the result of the acquisition of CPP, totaled approximately $5.3 million.

SCI CANADA AWARD EVENT TO SHOWCASE NATION'S DIVERSE SCIENTIFIC TALENT

Retrieved on: 
Wednesday, April 5, 2023
Science, University, Biochemistry, Grenfell Campus, Advanced Materials and Processes Research Institute, University of Ottawa, Government, Chemistry, Student, Chemical industry, COVID-19, Chemical engineering, PEI, UN, Memorial University of Newfoundland, Fanshawe College, Research, SCI, Perimeter Institute for Theoretical Physics, Management

/PRNewswire/ -- The best of Canada's scientific talent will debate its role in boosting economic growth at a special awards event on 18th April in Toronto.  Winners of the 2023 SCI Canada Awards include a pioneer in the polyethylene catalyst technology field, an adviser to the UN on water treatment, experts on chemistry in Inuit life and an innovator whose foundational science paved the way for the development of a Covid-19 vaccine.

Key Points: 
  • SCI Canada Award 2023 dinner, seminar and presentations to take place on 18th April in Toronto
    /PRNewswire/ -- The best of Canada's scientific talent will debate its role in boosting economic growth at a special awards event on 18th April in Toronto.
  • The winners will be formally honoured at an in-person dinner in Toronto with Dr Paul Smith due to receive the SCI Canada Medal.
  • Leaders from both science and business, including Canada's chemical and industrial community, will honour the achievements of SCI Canada Award and Student Merit Award Winners.
  • Dr Fiona Hess, Process Chemist and Member of the SCI Canada Committee will be the moderator of the panel.

Celyad Oncology reports full year 2022 financial results and recent business highlights

Retrieved on: 
Thursday, March 23, 2023
Intellectual property, Oncology, Probability, CET, EY, RCA, Bank statement, Article, Advanced Materials and Processes Research Institute, IP, Peter Stumpf (cellist), EDT, Sale, Research and development, CTMU, Annual report, Administration, Management, R, Research, Walloon, Cryptocurrency, Bookkeeping, Development

MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 ended December 31, 2022 and provides a business update.

Key Points: 
  • Research and Development (R&D) expenses were €18.9 million in 2022 as compared to €20.8 million in 2021, a year-over-year decrease of €1.8 million.
  • General and Administrative (G&A) expenses were €10.5 million in 2022 as compared to €9.9 million in 2021, an increase of €0.6 million.
  • A conference call will be held on Friday, March 24th at 1:00 p.m. CET / 8:00 a.m. EDT to review the financial and operating results for full year 2022.
  • Archived recording will be available in the " Events " section of the Celyad website after the event.

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 16, 2023
MSD, Multiple myeloma, CDK9, Advanced Materials and Processes Research Institute, MPM, Clinical trial, Financial toxicity, Neoplasm, Acquisition, Lymphoma, Merck & Co., Venetoclax, Acute myeloid leukemia, GPS, Doctor of Science, WT1, NCI, Merck, MYC, Research, Mesothelioma, PD, CR2, MD, Medication, Biomarker, Patient, Protocol, Bristol Myers Squibb, Bone marrow, SLS, D, National Cancer Institute, Azacitidine, Merck Sharp & Dohme Federal Credit Union, Ovarian cancer, AML, Pharmacokinetics, IND, Nivolumab, Cryptocurrency, Pharmaceutical industry, Greater China

NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2022 and provided a business update.

Key Points: 
  • This participation will trigger milestone payments totaling $13 million to SELLAS, which are expected during the first half of 2023.
  • Patient enrollment was completed at the end of 2022 and SELLAS expects to report topline data during the first half of 2023.
  • Opdivo® is a registered trademark of Bristol-Myers Squibb Company, New York, NY, USA and is not a trademark of SELLAS.
  • The manufacturers of these brands are not affiliated with and do not endorse SELLAS or its products.

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 10, 2022
Newton, Transfer, GLOBE, RNA transfection, Private Securities Litigation Reform Act, Immunity, General officer, Forward-looking statement, Leadership, U.S. Securities and Exchange Commission, Severe acute respiratory syndrome coronavirus 2, Nasdaq, Degenerative disease, Webcast, Research, Intention, SG, Technology, Conference call, Interest, General Administration of Sport of China, Therapy, R, SEC, Annual report, Antibody, ID, Infection, Safety, Company, Research and development, Program, Virology, Disease, Novartis, Immune system, Advanced Materials and Processes Research Institute, Security (finance), Administration, Vaccine, COVID-19, Pharmaceutical industry, Cryptocurrency, Pfizer, Omicron, Conference

WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022.

Key Points: 
  • ET
    WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022.
  • We look forward to advancing this important program into the clinic in the first quarter of 2023.
  • Dave had served as the companys interim chief executive officer and chief operating officer since February 2022.
  • In September, the Company announced that it will advance NVD200 into clinical trials in the first quarter of 2023.

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Acute myeloid leukemia, Immortalised cell line, Advanced Materials and Processes Research Institute, WT1, SPD, GLOBE, NEW, Clinical trial, CT, IND, Research, AML, MPM, CDK9, Patient, Cancer, Pembrolizumab, Company, COVID-19, Lymphoma, D, Acquisition, NMPA, SD, Nivolumab, Safety, GPS, NASDAQ, Payment, Second, Ovarian cancer, Toxic epidermal necrolysis, Mesothelioma, SLS, Pharmaceutical industry

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2022.

Key Points: 
  • Financial Results for the Second Quarter 2022:
    Licensing revenue: There was no licensing revenue for the second quarter of 2022 and $1.0 million for the first half of 2022, which related to Chinas NMPA approval of an IND application by 3D Medicines.
  • This compares to $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021.
  • R&D Expenses: Research and development expenses for the second quarter of 2022 were $5.5 million, compared to $3.5 million for the same period in 2021.
  • Acquired In-Process Research and Development: There was no acquired in-process research and development for the second quarter of 2022.

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

Retrieved on: 
Thursday, August 11, 2022
MDS, U.S. Securities and Exchange Commission, Disclosure, Advanced Materials and Processes Research Institute, GLOBE, R, Regulation Fair Disclosure, Clinical trial, Cancer, IPR, Lymphatic system, Board, TP53, Research, Patient, Executive, Acceleration, Research and development, Shareholder, Securities Act of 1933, Journal, Regulation, Securities Exchange Act of 1934, DNA repair, ATR, Director, Cell cycle, DNA, DDR, Biotechnology, Nasdaq, American Journal of Clinical Oncology, AML, Therapy, Acquisition, Program, Coronavirus, Azacitidine, FDA, Acute myeloid leukemia, IND, APRE, Company, Manuscript, Protein, WEE1, Administration, Pharmaceutical industry, Management

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Key Points: 
  • BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
  • Research and Development (R&D) expenses: R&D expenses were$6.8 millionfor the quarter endedJune 30, 2022, compared to$6.7 millionfor the comparable period in 2021.
  • General and Administrative (G&A) expenses: G&A expenses were$15.6 millionfor the quarter endedJune 30, 2022, compared to$3.3 millionfor the comparable period in 2021.
  • Acquired In-Process Research and Development (IPR&D) expenses: Acquired IPR&D expense was $76.0 million for the quarter ended June 30, 2022.

Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Allergy, Risk, American Academy, Company, Swelling, Research, Patient, Investment, Goal, NASDAQ, American Academy of Allergy, Asthma, and Immunology, Review, Therapy, Hereditary angioedema, Asthma, Half-life, Abdomen, COVID-19, D, FDA, Pharmacy, IND, Facebook, Bradykinin, Plasma, Time, Conference, Plasma kallikrein, Forward-looking statement, Instagram, IPR, Safety, Genetic disorder, LinkedIn, Twitter, Face, Acquisition, SEC, Drug discovery, Advanced Materials and Processes Research Institute, Annual report, Investigational New Drug, Fc receptor, Pharmaceutical industry, Vaccine, Online gambling, Fine chemical, Internet service provider, HAE

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • We expect initial results by year end, said Jill C. Milne, Ph.D., Chief Executive Officer of Astria.
  • The goal for STAR-0215 is to provide the most patient-friendly preventative treatment option for people living with HAE.
  • Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling.